MACITENTAN: THE EVOLUTION OF THE CLASS ENDOTHELIN RECEPTOR ANTAGONISTS TO IMPROVE EFFICACY AND SAFETY OF PAH TREATMENT
Pulmonary arterial hypertension (PAH) is a severe progressive disease, characterized by advanced remodeling of small pulmonary arteries and arterioles, which ultimately leads to right heart failure and death. Due to discovery of PAH pathophysiological targets, new medications have been developed and...
Saved in:
| Main Authors: | T. V. Martynuk, S. N. Nakonechnikov, I. Ye. Chazova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2013-06-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/5548 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01) -
CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01) -
NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynuk, et al.
Published: (2013-03-01) -
CLINICAL CASE: COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION
by: V. V. Bystrov, et al.
Published: (2014-12-01) -
ВОЗМОЖНОСТИ МЕДИКАМЕНТОЗНОГО ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ ТРОМБОЭМБОЛИЧЕСКОЙ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ
by: Т. В. Мартынюк, et al.
Published: (2015-07-01)